IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells (Q101476400)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

title

IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Qifa Liu

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Peilong Lai

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Xin Du

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Robert Weinkove

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Duanqing Pei

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Yao Yao

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Peng Li

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

author name string

Zhiwu Jiang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Rui Liao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Shanglin Li

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Diwei Zheng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Le Qin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Di Wu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Suimin Chen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Youguo Long

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Qiting Wu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Suna Wang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Simiao Lin

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Xiaohan Huang

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Zhaoyang Tang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Pengcheng Shi

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Hongsheng Zhou

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Ruocong Zhao

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Yangqiu Li

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Yang Jie

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Wei Wei

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Shuzhong Cui

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

Pentao Liu

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

publication date

9 November 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

11 November 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Current concepts in the diagnosis and management of cytokine release syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

IL-6 in inflammation, immunity, and disease

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

IL-6 trans-signaling-dependent rapid development of cytotoxic CD8+ T cell function

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

A bioactive designer cytokine for human hematopoietic progenitor cell expansion

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Paths to stemness: building the ultimate antitumour T cell.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Blastocyst-like structures generated solely from stem cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Preferential heterodimer formation by isolated leucine zippers from fos and jun

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

Bone corticalization requires local SOCS3 activity and is promoted by androgen action via interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

A STAT3-based gene signature stratifies glioma patients for targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41375-020-01085-1

7 January 2021

10.1038/S41375-020-01085-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33168950%20AND%20SRC:MED&resulttype=core&format=json

11 November 2020

1 reference